Anna B Fishbein1, Brian T Cheng2, Caroline C Tilley3, Wendy Smith Begolka4, Adam C Carle5, Christopher B Forrest6, Phillis C Zee7, Amy S Paller2, James W Griffith8. 1. Division of Allergy-Immunology, Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Ill. Electronic address: AFishbein@luriechildrens.org. 2. Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Ill; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Ill. 3. Division of Allergy-Immunology, Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Ill. 4. National Eczema Association, Novato, Calif. 5. Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati College of Medicine, Cincinnati, Ohio; Department of Psychology, University of Cincinnati College of Arts and Sciences, Cincinnati, Ohio. 6. Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pa. 7. Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Ill. 8. Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Ill.
Abstract
BACKGROUND: Atopic dermatitis (AD) causes sleep disturbance but the epidemiology is not known. OBJECTIVE: To estimate the US prevalence of sleep disturbance and its impact on psychological and neurocognitive function. METHODS: We conducted a cross-sectional survey of 180 parent-child dyads with AD using stratified sampling based on disease severity (Patient Oriented Eczema Measure: mild [n = 30), moderate (n = 75) or severe (n = 75]), age, and race (White or Black or African American or other). Symptoms of sleep and psychologic health were assessed using the Patient-Reported Outcome Measurement Information System. To estimate the prevalence of sleep disturbance, we calculated weights using poststratification adjustment making marginal frequencies of AD severity, race, and age similar to marginal frequencies in the 2007 National Survey of Children's Health. Unweighted regression models examined associations with sleep disturbance. RESULTS: In children age 5 to 17 years with AD, we estimated that sleep disturbance occurred in 66.9% (95% confidence interval, 53.3% to 80.5%; 3,116,305 children). The odds of severe sleep disturbance (worse than 95% of US children) were highest in moderate to severe versus mild AD (2.03 [1.00-4.10]; P = .0495; compared with 8.68 [1.82-41.49]; P = .0068). Predictors of parent proxy-reported sleep disturbance were itch intensity (adjusted β [95% confidence interval] 1.33 [0.62-2.04]) and low income (<$50,000: 6.64 [2.05-11.23]; and $50,000 to less than 100,000: 4.75 [0.35-9.14]). Controlling for disease severity, itch intensity, and significant sociodemographics-parent-proxy, reported sleep disturbance was associated with increased severity of sleep-related impairment, depression, fatigue, and anxiety, in addition to worse inattention and impulsivity. In fully adjusted models, children who self-reported sleep disturbance (T-score ≥60) had increased odds of sleep-related impairment (1.20 [1.11-1.29]), depression (1.13 [1.03, 1.24]), fatigue (1.28 [1.06-1.54]), and anxiety (1.16 [1.02-1.31]). CONCLUSIONS: Sleep disturbance is a common symptom of AD. It affects about 3 million US children and is associated with neuropsychiatric impairment, including depression, anxiety, and inattention. Clinicians should screen for these symptoms in school-aged children, particularly those with moderate to severe AD.
BACKGROUND: Atopic dermatitis (AD) causes sleep disturbance but the epidemiology is not known. OBJECTIVE: To estimate the US prevalence of sleep disturbance and its impact on psychological and neurocognitive function. METHODS: We conducted a cross-sectional survey of 180 parent-child dyads with AD using stratified sampling based on disease severity (Patient Oriented Eczema Measure: mild [n = 30), moderate (n = 75) or severe (n = 75]), age, and race (White or Black or African American or other). Symptoms of sleep and psychologic health were assessed using the Patient-Reported Outcome Measurement Information System. To estimate the prevalence of sleep disturbance, we calculated weights using poststratification adjustment making marginal frequencies of AD severity, race, and age similar to marginal frequencies in the 2007 National Survey of Children's Health. Unweighted regression models examined associations with sleep disturbance. RESULTS: In children age 5 to 17 years with AD, we estimated that sleep disturbance occurred in 66.9% (95% confidence interval, 53.3% to 80.5%; 3,116,305 children). The odds of severe sleep disturbance (worse than 95% of US children) were highest in moderate to severe versus mild AD (2.03 [1.00-4.10]; P = .0495; compared with 8.68 [1.82-41.49]; P = .0068). Predictors of parent proxy-reported sleep disturbance were itch intensity (adjusted β [95% confidence interval] 1.33 [0.62-2.04]) and low income (<$50,000: 6.64 [2.05-11.23]; and $50,000 to less than 100,000: 4.75 [0.35-9.14]). Controlling for disease severity, itch intensity, and significant sociodemographics-parent-proxy, reported sleep disturbance was associated with increased severity of sleep-related impairment, depression, fatigue, and anxiety, in addition to worse inattention and impulsivity. In fully adjusted models, children who self-reported sleep disturbance (T-score ≥60) had increased odds of sleep-related impairment (1.20 [1.11-1.29]), depression (1.13 [1.03, 1.24]), fatigue (1.28 [1.06-1.54]), and anxiety (1.16 [1.02-1.31]). CONCLUSIONS: Sleep disturbance is a common symptom of AD. It affects about 3 million US children and is associated with neuropsychiatric impairment, including depression, anxiety, and inattention. Clinicians should screen for these symptoms in school-aged children, particularly those with moderate to severe AD.
Authors: Anna B Fishbein; Kelly Mueller; Lacey Kruse; Peter Boor; Stephen Sheldon; Phyllis Zee; Amy S Paller Journal: J Am Acad Dermatol Date: 2017-10-28 Impact factor: 11.527
Authors: Jennifer C Li; Anna Fishbein; Vivek Singam; Kevin R Patel; Phyllis C Zee; Hrayr Attarian; David Cella; Jonathan I Silverberg Journal: Dermatitis Date: 2018 Sep/Oct Impact factor: 4.845
Authors: Alison D Treister; Heather Stefek; Daniela Grimaldi; Neil Rupani; Phyllis Zee; Jeremy Yob; Stephen Sheldon; Anna B Fishbein Journal: J Clin Sleep Med Date: 2019-08-15 Impact factor: 4.062
Authors: Danny Camfferman; John D Kennedy; Michael Gold; Alfred J Martin; Kurt Lushington Journal: Sleep Med Rev Date: 2010-04-14 Impact factor: 11.609
Authors: Kathryn Lemery-Chalfant; Jane E Schreiber; Nicole L Schmidt; Carol A VAN Hulle; Marilyn J Essex; H H Goldsmith Journal: J Am Acad Child Adolesc Psychiatry Date: 2007-10 Impact factor: 8.829
Authors: Faustine D Ramirez; Shelley Chen; Sinéad M Langan; Aric A Prather; Charles E McCulloch; Sharon A Kidd; Michael D Cabana; Mary-Margaret Chren; Katrina Abuabara Journal: JAMA Dermatol Date: 2019-05-01 Impact factor: 10.282
Authors: J I Silverberg; J M Gelfand; D J Margolis; M Boguniewicz; L Fonacier; M H Grayson; P Y Ong; Z C Chiesa Fuxench; E L Simpson Journal: Br J Dermatol Date: 2019-03-05 Impact factor: 9.302
Authors: Brian T Cheng; Mallika S Patel; Mindy Xu; Caroline C Tilley; Phyllis C Zee; Amy S Paller; Anna B Fishbein Journal: Ann Allergy Asthma Immunol Date: 2022-02-04 Impact factor: 6.248
Authors: Nina Y Zhou; Amanda Nili; Courtney K Blackwell; Nonye Ogbuefi; Peter Cummings; Jin-Shei Lai; James W Griffith; Amy S Paller; Lauren S Wakschlag; Anna B Fishbein Journal: Pediatr Dermatol Date: 2021-12-21 Impact factor: 1.997